OBJECTIVE: Tolerance of and complications caused by minimally invasive hysterectomy and staging in the older endometrial cancer population is largely unknown despite the fact that this is the most rapidly growing age group in the United States. The objective of this retrospective review was to compare operative morbidity by age in patients on the Gynecologic Oncology Group Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus (LAP2) trial. STUDY DESIGN: This is a retrospective analysis of patients from Gynecologic Oncology Group LAP2, a trial that included clinically earlystage uterine cancer patients randomized to laparotomy vs laparoscopy for surgical staging. Differences in the rates and types of intraoperative and perioperative complications were compared by age. Specifically complications between patients <60 vs !60 years old were compared caused by toxicity analysis showing a sharp increase in toxicity starting at age 60 years in the laparotomy group. RESULTS: LAP2 included 1477 patients !60 years old. As expected, with increasing age there was worsening performance status and disease characteristics including higher rates of serous histology, high-stage disease, and lymphovascular space invasion. There was no significant difference in lymph node dissection rate by age for the entire population or within the laparotomy or laparoscopy groups. Toxicity analysis showed a sharp increase in toxicity seen in patients !60 years old in the laparotomy group. Further analysis showed that when comparing laparotomy with laparoscopy in patients <60 years old vs !60 years old and controlling for race, body mass index, stage, grade, and performance status, patients <60 years old undergoing laparotomy had more hospital stays >2 days (odds ratio, 17.48; 95% confidence interval, 11.71e27.00, P < .001) compared with patients <60 years old undergoing laparoscopy. However, when comparing laparotomy with laparoscopy in patients !60 years old, in addition to hospital stay >2 days (odds ratio, 12.77; 95% confidence interval, 8.74e19.32, P < .001), there were higher rates of the following postoperative complications: antibiotic administration (odds ratio, 1.63; 95% confidence interval, 1.24e2.14, P < .001), ileus (odds ratio, 2.16; 95% confidence interval, 1.42e3.31, P <0.001), pneumonias (odds ratio, 2.36; 95% confidence interval, 1.01e5.66, P ¼ .048), deep vein thromboses (odds ratio, 2.87; 95% confidence interval, 1.08e8.03, P ¼ .035), and arrhythmias (odds ratio, 3.21; 95% confidence interval, 1.60e6.65, P ¼ .001) in the laparotomy group. CONCLUSION: Laparoscopic staging for uterine cancer is associated with decreased morbidity in the immediate postoperative period in patients !60 years old. These results allow for more accurate preoperative counseling. A minimally invasive approach to uterine cancer staging may decrease morbidity that could affect long-term survival.
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Key words: endometrial, LAP2, older E ndometrial cancer, which is predominantly a disease of postmenopausal women, is expected to increase in prevalence with an increasingly aged and obese population. In 2017, there will be an estimated 61,380 cases of endometrial cancer diagnosed in the United States and 10,920 deaths. 1 Despite the increased rates of endometrial cancer mortality seen in older patients, studies show these patients receive less surgical and adjuvant therapy than their younger counterparts, which is, in part, due to the fact that treating physicians believe older patients cannot tolerate such therapy. This view is supported by literature showing that advanced age is an independent risk factor for perioperative morbidity, even when controlling for medical comorbidities. 2 Minimally invasive surgical (MIS) management is used for many types of cancers. There is a significant amount of data showing similar oncological outcomes and decreased morbidity with minimally invasive techniques vs laparotomy (LAP). 3, 4 Most recently, the Laparoscopic Approach to Cancer of the Endometrium trial was reported. This randomized phase 3 trial compared exploratory laparotomy with total laparoscopic hysterectomy (TLH) with or without lymph node dissection in clinical stage I endometrioid endometrial cancer. They demonstrated no difference in disease-free survival. While age !65 years was a prognostic factor for disease recurrence (hazard ratio, 3.14 [1.57-6.26]), no separate analysis of complications among study participants, including the 44% who were !65 years old was presented in this paper. How well older patients tolerate each of these surgical options remains unknown. Several retrospective studies show decreased morbidity in older patients managed with minimally invasive techniques; however, there are no prospective data comparing outcomes in older patients. [6] [7] [8] [9] In 1996, the Gynecologic Oncology Group (GOG) opened a randomized, prospective clinical trial (GOG-2222 Results showed improved quality of life and decreased complication in the LAVH group with no decrement in survival in patients managed with laparoscopy compared with laparotomy. LAP2 is the largest prospective trial to date looking at minimally invasive surgical approaches in clinically early-stage endometrial cancer. Our current study includes all patients from LAP2 with 1477 patients !60 years old. This allows for the assessment of a large subset of older patients with clinically early-stage endometrial cancer. 10, 11 The goal of this ancillary review was to compare intraoperative, perioperative, and postoperative surgical morbidity outcomes in LAVH vs LAP by age in patients who participated in the GOG LAP2 trial. The GOG LAP2 trial included patients with primarily early-stage disease and good performance status and required complete surgical staging, making this a highly selected patient population. The results from this study will allow clinicians to more accurately evaluate the benefits of surgery and its potential complications in older endometrial cancer patients.
Materials and Methods
This was an analysis of patients who were enrolled in LAP-2, a GOG clinical trial. The details of inclusion and exclusion criteria were reported in the original manuscript. 10 Briefly, the study was designed to compare LAVH with LAP for the purpose of complete comprehensive surgical staging of uterine cancer.
The primary outcome of the study was recurrence-free survival. Other endpoints included perioperative adverse events, LAVH conversion to LAP, length of hospital stay after surgery, operative time, quality of life, sites of recurrence, and survival. Eligibility requirements were clinical stage I to IIA uterine cancer, adequate bone marrow, renal and hepatic function, and GOG performance status of less than 4. All patients gave written informed consent prior to study entry in compliance with local institutional review board and federal guidelines.
In our current study, surgical outcomes were compared between patients by age. While it is generally agreed upon in the literature that elderly is defined as >65 or 70 years old, our initial toxicity data showed increased toxicity starting at age 60 years; therefore, our results show surgical outcomes compared between patients <60 years old vs !60 years old.
The same analysis was performed using an age cutoff of 70 years old and similar results were found. An intentionto-treat analysis was used for the assessment of surgical complications. The perioperative time period included the first 30 days after surgery and the postoperative time period included up to 6 weeks after the surgery. These parameters were set by the LAP2 protocol.
For statistical analysis, categorical variables were compared between the patient subgroups by the Pearson c 2 test 12 and continuous variables by the Wilcoxon-Mann-Whitney test 13 or the Kruskal-Wallis test.
14 A logistic regression model was used to evaluate specific operative morbidities and to estimate their covariate-adjusted odds of following LAVH or LAP. A linear regression model was used to estimate the covariate-adjusted relationships of patients' independent baseline factors to severe toxicity. The nonlinearity of the effect of continuous variables was assessed using restricted cubic splines. 15 All statistical tests were 2 tailed with the significance level set at alpha ¼ 0.05. Statistical analyses were performed using the R programming language and environment. 16 Institutional Review Board and Institutional Biosafety Committee approvals were obtained at each institution, and all eligible patients signed an informed consent before study entry in compliance with institutional, state, and federal regulations. Permission to perform this retrospective analysis was obtained from the GOG.
Results

LAP2 population demographics, pathology, and outcomes
From the total LAP2 population, 762 patients are 60-69 years old, and 715 patients are !70 years old. Demographic data, including BMI, performance status, disease characteristics, postoperative therapy, recurrence, and survival by decade of age, are shown in Table 1 . As age increases, BMI decreases (P < .001) and performance status worsens (P < .001), and when looking at disease characteristics, there are increasing rates of serous histology (P < .001), higherstage disease (P < .001), and more lymphovascular space invasion (P < .001).
The majority of patients on LAP2 had endometrioid or serous histology, so only these histologies are shown in Table 1 but all histological subtypes were included in the analysis. When looking at survival by age, older patients have significantly higher rates of recurrence (P < .001) and higher rates of death because of disease (P < .001). With increasing age, there is also a higher rate of conversion to LAP (<50 years old, 23.8% vs !80 years old, 36.8%; P ¼ .003 for all ages).
Although full surgical staging was required in GOG LAP2, not all patients underwent complete lymph node dissection. While a small percentage of patients had only pelvic or only
Original Research GYNECOLOGY ajog.org TABLE 1 Pathology and outcomes by age (years) Table 1 ). There was no significant difference in lymph node dissection rate by age for the entire population or within the LAP or LAVH groups.
Intraoperative, postoperative, and perioperative complications by age
Complication rates were broken down into surgical approach and age. In the LAP group (n ¼ 886), there were no significant differences in intraoperative complication rates by age. Postoperatively, there were increased rates of complications by age with the increase observed starting at age 60 years old (16.3% in those <60 years old vs 24.5% in those !60 years old, P ¼ .002 for all age groups). Postoperative complications that increase with age include urinary tract infections (2.7% vs 13% in patients <50 years old vs !80 years old, P <.001 for all age groups), pneumonias (0.9% vs 9.3% in patients <50 years old vs !80 years old, P ¼ .006 for all age groups), congestive heart failure (0% vs 2.7% in patients <50 years old vs !80 years old, P ¼ .016 for all age groups), and arrhythmias (0% vs 2.7% in patients <50 years old vs !80 years old, P <.001 for all age groups).
Deep vein thrombosis also increased with increasing age (0% vs 5.6% in patients <50 years old vs !80 years old, P ¼ .05 for all age groups). Rates of readmission (3.5% vs 14.8% in patients <50 years old vs !80 years old, P ¼ .022 for all age groups) and treatment-related deaths increased significantly with increasing age as well, with a treatmentrelated mortality rate of 0% in patients <50 years old vs 5.6% in patients !80 years old (P ¼ .005 for all age groups) ( Table 2 ).
In the LAVH group (n ¼ 1630), there were no differences in intraoperative complication rates by age; and postoperatively, the only difference is increasing rates of hospitals stay >2 days with increasing age (43.6% vs 68.9% in patients <50 years old vs !80 years old, P < .001 for all age groups) (Table 3) .
Overall, there was a higher rate of complication in the LAP group, and this difference got larger with increasing age, starting at age 60 years. Patients <50 years old had the same rates of postoperative complications (LAP, 15.9%, vs LAVH, 15.7%), while older, and especially the very old (patients !80 years old), had increasing rates of complications after LAP (38.9% vs LAVH, 19.8%).
Intraoperative, postoperative, and perioperative complications by age and surgical approach Figure, the change in maximum toxicity before approximately age 60 years is not significant, but after age 60 years, the toxicity appears to increase sharply, with the surgical approach by age interaction with a moderate effect (P ¼ .035). Therefore, as age increases, the benefit from LAVH appears to increase as well, and according to this model, the benefit occurs beginning at age 60 years.
Based on the increasing rates of complications seen starting at age 60 years old in the LAP group in this study, we used 60 years old as our cutoff and next compared complications in LAP vs LAVH, controlling for race, BMI, stage, grade, and performance status. In patients <60 years old, there were no differences in intraoperative complications by surgical approach. In the postoperative period, as expected, the LAP group had higher rates of a hospital stay >2 days (odds ratio [OR], 17.48; 95% confidence interval [CI], 11.71e27.00, P < .001) (Supplemental Table 2 ).
In patients !60 years old (Table 4 ), the only difference in intraoperative complications was arterial injury, which occurred more frequently in the LAVH group (OR, 0.31; 95% CI, 0.07e0.94, P ¼ .037). The original LAP2 manuscript stated that the majority of these were controlled without conversion to LAP. The postoperative time period revealed more differences in complications by surgical approach in older patients. In addition to hospital stay >2 days (OR, 12.77; 95% CI, 8.74e19.32, P < .001), patients !60 (Table 4) .
Comment
This analysis shows a clear difference in morbidity associated with surgical approach in older endometrial cancer patients. Results from this analysis show that while there are overall low rates of intraoperative and postoperative complications during complete surgical staging, regardless of surgical approach, patients undergoing LAP experience more postoperative complications with increasing age.
An increased benefit to laparoscopic staging is seen beginning at age 60 years old, with increased toxicity seen in the LAP group, starting at this age. In patients <60 years old, there is very little difference in complication rates between LAVH and LAP, and these patients generally do well from a surgical standpoint, with higher rates of expected complications from LAP such as longer hospital stay. Complications and adverse events by age (laparoscopy, n [1630) 
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In contrast, patients !60 years old who undergo LAP have higher rates of additional complications compared with LAVH such as ileus, deep vein thrombosis, pneumonia, and cardiac adverse events (arrhythmias), suggesting that these patients truly benefit from a minimally invasive approach. It is important to note that this study included relatively healthy patients who met inclusion criteria for a surgical study, and therefore, these results may not be applicable to advanced-stage patients or patients with poor performance status and do not account for medical comorbidities.
A recent Surveillance, Epidemiology, and End Results analysis highlights the increased morbidity seen in older patients undergoing LAP for surgical management of endometrial cancer. This study examined more than 25,000 women !65 years old who underwent hysterectomy for endometrial cancer. Compared with women 65e69 years old, women !85 years old were more likely to have perioperative complications (12% vs 17%), postoperative medical complications (24% vs 34%), longer hospital stay (3 vs 5 days), and require more blood transfusions (6% vs 10%). Perioperative mortality rates were significantly higher in patients !85 years old compared with those 65e69 years old (1.6% vs 0.4%). These results were the same when controlling for medical comorbidities. This study population included all stages and medical comorbidities, and not all patients underwent staging, so it differs from our population but demonstrates the morbidity of LAP in elderly patients. 2 Studies from the colorectal literature have looked at the potential benefits of laparoscopic colorectal surgery compared with laparotomy in the elderly with concern for worse outcomes in this population because of the increase in operative time. In 727 patients, the laparoscopic patients did have longer operating times compared with laparotomy but the length of stay was significantly shorter in the laparoscopic group, and there was no significant difference in the median recovery of bowel function and postoperative morbidity. Thirty day mortality was significantly lower in the laparoscopic arm (1.3% vs 4.6%, P ¼ .03).
17
In addition to the immediate effects of intraoperative and postoperative morbidity, perioperative complications are also important for survival. A large study looking at 30 day mortality and long-term survival after major surgery found that a 30 day postoperative complication was more important than preoperative patient risk and intraoperative factors in determining survival after major surgery. 18 This suggests that postoperative complications do not affect just immediate recovery but also potentially survival, perhaps because of the loss of reserve and the inability to start or complete additional therapy.
The requirement for complete surgical staging in LAP2 is a strength of this study, making it a true evaluation of operative morbidity in a fully staged population. This sets this group of older patients apart from other studies in which a large percentage of older patients did not undergo lymph node dissection. However, the requirement for full staging may also have an impact on some of the complications noted in the study. LAP2 took place at a time when there was a steep learning curve for laparoscopy in general and especially for lymph nodes. Because full lymph node dissection was required, patients were converted from LAVH to LAP when a full dissection could not be completed. The prevalence of conversion among the entire population and especially among the older patients is much higher than would be expected in a more contemporary population and should be viewed through that lens.
Weaknesses of this study include the retrospective nature of the analysis and the performance status and early clinical stage required for eligibility in LAP2, making results less applicable to patients with poor performance status and advanced-stage disease. Additionally, this study uses age 60 years to define elderly patients. This age was used based on our toxicity data ( Figure) but is generally younger than age 65 or 70 years, which is commonly used in the literature. Additional analysis of our data using 70 years old at the cutoff age shows similar results (data not shown).
Finally, peri-and postoperative care has advanced since the publication of 
Relationship between age and maximum toxicity for each treatment group
This is a linear model with outcome maximum toxicity. The model shows a treatment Â age interaction with a moderate effect (P ¼ .035). The effects plot suggests that the LAP group is prone to higher maximum toxicity after about age 60 years. Original Research GYNECOLOGY ajog.org LAP2, with increased incorporation of enhanced recovery after surgery protocols, evidence based use of anticoagulation, increased expertise for MIS procedures among our anesthesia colleagues, and most recently incorporation of sentinel lymph node identification into LAVH or RaTLH instead of full lymphadenectomy. 19 All of these have an impact on expected complications following MIS procedures in the present day, and we can assume the complication rates noted in this retrospective analysis are higher than what we would expect under current practice. Despite this, the increased benefit of LAVH as compared with LAP with age should reassure treating physicians that MIS procedures are not only safe but also safer for older patients with endometrial cancer.
With the widespread incorporation of RaTLH into the care of patients with endometrial cancer, the question arises of how these LAVH vs LAP results inform the use of RaTLH. While there are no large randomized Recent retrospective studies have compared outcomes in elderly endometrial cancer patients undergoing staging with robotics vs LAP. These studies show that elderly patients (defined as 65e70 years old) have overall increased rates of perioperative morbidity but that robotic staging in this population is associated with decreased perioperative morbidity and a higher incidence of completion of lymphadenectomy compared with LAP. [7] [8] [9] If anything, RaTLH appears as safe as LAVH, and our data reinforce the incorporation of MIS procedures preferentially into the care of older endometrial cancer patients.
In summary, our results demonstrate that performing laparoscopic staging for uterine cancer is not just more convenient for surgeons and patients but also is associated with decreased morbidity in patients !60 years old in the immediate postoperative period. This includes lower cardiovascular and infectious complications.
These results allow clinicians to provide more accurate counseling about risks and benefits of surgery to older uterine cancer patients and highlight the importance of offering a minimally invasive approach to decrease immediate postoperative morbidity that could potentially have an impact on longerterm outcomes. 
